Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Guidance

Subcategories:Clinical Criteria/GuidelinesEthicsLegal UpdatesLegislation & AdvocacyMeeting ReportsResearch Rheum

Figure 2: High-resolution computed tomography showed evidence of interstitial lung disease.

High-resolution computed tomography shows evidence of ILD.

The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

 

In the Wake of Dobbs v. Jackson Women’s Health Organization

Mary Beth Nierengarten  |  May 10, 2023

Since the Supreme Court ruling in June 2022 overturning 50 years of precedent protecting abortion as a constitutional right (Dobbs v. Jackson Women’s Health Organization), states are enacting and implementing new laws to regulate abortion, and medical organizations and healthcare providers are assuming the large task of understanding what the new laws mean for their…

ACR Expresses Concerns with MedPAC’s Drug Pricing Recommendations

From the College  |  May 9, 2023

In April, the Medicare Payment Advisory Committee voted to recommend a change in the add-on payment for Part B drugs, including reducing payment for more expensive drugs. The ACR sent a letter to MedPAC expressing concerns about the significant impacts such policies would have on rheumatologists.

2 AC&R Study Summaries: Racial Disparities in Lupus Trials & Post-Discharge Follow-Up in Lupus

Arthritis Care & Research  |  May 9, 2023

Racial Disparities in Lupus Clinical Trial Participation By Saira Z. Sheikh, MD Why was this study done? Lupus disproportionately affects Black and Latino populations, particularly women in childbearing years. Clinical trials of patients with lupus can advance the development of therapeutics and access to better treatments, as well as improve health outcomes for patients. However,…

Complain Constructively: It’s Called Advocacy

Belinda Birnbaum, MD  |  May 8, 2023

It’s easy for rheumatologists and rheumatology professionals to feel frustrated by burdensome administrative tasks, complicated insurance policies and other healthcare hurdles. Advocacy offers a way to channel those complaints into constructive action, says Belinda Birnbaum, MD.

A Conversation with Rheumatology Research Foundation VP Liana Fraenkel, MD, MPH

Leslie Mertz, PhD  |  May 5, 2023

Liana Fraenkel, MD, MPH, likes to fix things, and the dynamic and challenging field of rheumatology always has room for improvement. That mindset has led her down some interesting paths as a researcher and healthcare provider, and as vice president of the Rheumatology Research Foundation. Dr. Fraenkel was a rheumatologist and researcher at the Yale…

The Effect of Upadacitinib on Bone Erosion in Patients with RA

Michele B. Kaufman, PharmD, BCGP  |  May 2, 2023

Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.

Peresolimab Promising for RA

Michele B. Kaufman, PharmD, BCGP  |  May 1, 2023

Stimulating human programmed cell death protein 1 (PD-1), a checkpoint inhibitory receptor, with peresolimab may be a viable way to treat autoimmune diseases, according to a study by Tuttle et al. In the study, patients with active rheumatoid arthritis (RA) who were treated with peresolimab experienced greater improvements in disease activity than those who received placebo.

Sunny San Diego to Welcome ACR Convergence 2023

Vanessa Caceres  |  May 1, 2023

An in-person poster hall and networking lounges are among the highlights attendees can expect at ACR Convergence 2023 in San Diego, Nov. 10–15.

JAK Inhibitors vs. TNF Inhibitors: Understanding Infection Risks

Michele B. Kaufman, PharmD, BCGP  |  April 27, 2023

Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.

Help Your Legislators Understand the Ins & Outs of Patient Care

Christina Downey, MD  |  April 25, 2023

With an influx of new faces in the 118th Congress, Government Affairs Committee Chair Christina Downey, MD, notes that now is a great time to establish a relationship with your member of Congress and help them understand the day-to-day of what it takes to take care of patients.

  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 309
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences